Delcath Systems Inc

Delcath’s directors received $0.00‑exercise stock options as the FDA grants Breakthrough status to its liquid‑jet HCC system, boosting investor confidence and linking executive rewards to clinical milestones.

Delcath Systems insider buying signals confidence in upcoming clinical or regulatory milestones, but investors must weigh high risk against potential growth in liver‑cancer therapy.